MX2010005055A - Modulacion de la expresion del factor 7. - Google Patents

Modulacion de la expresion del factor 7.

Info

Publication number
MX2010005055A
MX2010005055A MX2010005055A MX2010005055A MX2010005055A MX 2010005055 A MX2010005055 A MX 2010005055A MX 2010005055 A MX2010005055 A MX 2010005055A MX 2010005055 A MX2010005055 A MX 2010005055A MX 2010005055 A MX2010005055 A MX 2010005055A
Authority
MX
Mexico
Prior art keywords
factor
antisense compounds
modulation
expression
embolism
Prior art date
Application number
MX2010005055A
Other languages
English (en)
Inventor
Hong Zhang
Susan M Freier
Brett P Monia
Jeffrey R Crosby
Chenguang Zhao
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of MX2010005055A publication Critical patent/MX2010005055A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen en la presente compuestos de antisentido y métodos para disminuir el Factor 7 y para tratar o prevenir complicaciones tromboembólicas, trastornos hiperproliferativos o condiciones inflamatorias en un individuo con necesidad de los mismos. Ejemplos de condiciones de enfermedad que pueden mejorar con la administración de los compuestos de antisentido dirigidos al Factor 7 incluyen trombosis, embolia y tromboembolia, tal como la trombosis de vena profunda, embolia pulmonar, infarto al miocardio, accidente cerebrovascular, cáncer, artritis reumatoide y fibrosis.
MX2010005055A 2007-11-09 2008-11-05 Modulacion de la expresion del factor 7. MX2010005055A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98692807P 2007-11-09 2007-11-09
PCT/US2008/082526 WO2009061851A2 (en) 2007-11-09 2008-11-05 Modulation of factor 7 expression

Publications (1)

Publication Number Publication Date
MX2010005055A true MX2010005055A (es) 2010-06-25

Family

ID=40417602

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005055A MX2010005055A (es) 2007-11-09 2008-11-05 Modulacion de la expresion del factor 7.

Country Status (13)

Country Link
US (1) US9029337B2 (es)
EP (2) EP2227545A2 (es)
JP (1) JP2011502514A (es)
KR (1) KR20100105550A (es)
CN (1) CN102076852A (es)
AU (1) AU2008323970B2 (es)
BR (1) BRPI0820391A2 (es)
CA (1) CA2705316A1 (es)
IL (1) IL205536A0 (es)
MX (1) MX2010005055A (es)
NZ (1) NZ585250A (es)
RU (1) RU2010119775A (es)
WO (1) WO2009061851A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120214862A1 (en) * 2009-07-16 2012-08-23 Isis Pharmaceuticals, Inc. Modulation of factor 7 expression
WO2011123394A1 (en) * 2010-03-31 2011-10-06 Isis Pharmaceuticals, Inc. Modulation of matrix metalloproteinase 13 (mmp-13) expression
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
ES2633565T3 (es) 2010-11-12 2017-09-22 The General Hospital Corporation ARN no codificantes asociados a polycomb
AU2011349464B2 (en) * 2010-12-20 2016-07-07 The General Hospital Corporation Polycomb-associated non-coding RNAS
DK2655621T3 (en) * 2010-12-20 2018-08-13 Massachusetts Gen Hospital Polycomb-associated non-coding RNAS
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
WO2012174154A1 (en) * 2011-06-13 2012-12-20 Isis Pharmaceuticals, Inc. Modulation of inflammatory responses by factor vii
WO2013022984A1 (en) 2011-08-11 2013-02-14 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
KR101840512B1 (ko) * 2011-09-20 2018-03-20 아이오니스 파마수티컬즈, 인코포레이티드 Gcgr 발현의 안티센스 조절
EP3330278A1 (en) * 2012-02-08 2018-06-06 Ionis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
JP2015507924A (ja) * 2012-02-08 2015-03-16 アイシス ファーマシューティカルズ， インコーポレーテッド 第ｖｉｉ因子の発現を調節するための方法と組成物
US10273474B2 (en) 2012-03-30 2019-04-30 Washington University Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
EP3336189A1 (en) 2012-04-20 2018-06-20 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10174323B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating ATP2A2 expression
CA2873779A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating mecp2 expression
EP2850185A4 (en) 2012-05-16 2015-12-30 Rana Therapeutics Inc COMPOSITIONS AND METHODS FOR MODULATING UTRN EXPRESSION
US10059941B2 (en) 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
AU2013262700A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating hemoglobin gene family expression
US9695418B2 (en) 2012-10-11 2017-07-04 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleosides and uses thereof
US20150275208A1 (en) 2012-10-12 2015-10-01 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
RU2730677C2 (ru) * 2012-10-15 2020-08-24 Ионис Фармасьютикалз, Инк. Соединение для модуляции экспрессии гена c9orf72 и его применение
CN104955952A (zh) 2013-01-30 2015-09-30 弗·哈夫曼-拉罗切有限公司 Lna寡核苷酸碳水化合物缀合物
SI2992009T1 (sl) 2013-05-01 2020-10-30 Ionis Pharmaceuticals, Inc. Sestavki in postopki za moduliranje izražanja apolipoproteina (A)
TWI772856B (zh) * 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
EP3058098A4 (en) * 2013-10-18 2017-03-22 Institut de Cardiologie de Montréal Genotyping tests and methods for evaluating plasma creatine kinase levels
MX2016014013A (es) 2014-05-01 2016-11-15 Ionis Pharmaceuticals Inc Composiciones y metodos para modular la expresion del receptor de la hormona del crecimiento.
WO2015179693A1 (en) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US10858650B2 (en) 2014-10-30 2020-12-08 The General Hospital Corporation Methods for modulating ATRX-dependent gene repression
BR112017017178A2 (pt) * 2015-02-26 2018-04-03 Ionis Pharmaceuticals Inc moduladores específicos de alelo de rodopsina de p23h
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
US11400161B2 (en) 2016-10-06 2022-08-02 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6001992A (en) 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US6180403B1 (en) 1999-10-28 2001-01-30 Isis Pharmaceuticals Inc. Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
ES2242291T5 (es) 1997-09-12 2016-03-11 Exiqon A/S Análogos de nucleósidos bicíclicos y tricíclicos, nucleótidos y oligonucleótidos
US20030228597A1 (en) * 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
EP1499627A2 (en) 2001-07-03 2005-01-26 ISIS Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
US20030087244A1 (en) * 2001-10-09 2003-05-08 Vitivity, Inc Diagnosis and treatment of vascular disease
ES2226533B1 (es) * 2002-07-25 2005-12-16 Fundacio Privada I Institut De Recerca De L'hospital De La Santa Creu I Sant Pau Nuevas variantes alelicas en el gen del factor vii.
AU2003268096A1 (en) 2002-08-14 2004-03-03 Pharmacia Corporation ANTISENSE MODULATION OF Nav1.3 EXPRESSION
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
EP2284266B1 (en) 2002-11-14 2013-11-06 Thermo Fisher Scientific Biosciences Inc. siRNA targeting tp53
WO2004092325A2 (en) * 2002-12-24 2004-10-28 Board Of Regents, The University Of Texas System Screening methods using zebrafish to identify thrombotic and anti-thrombotic compounds and genes
US7202264B2 (en) * 2003-01-31 2007-04-10 Isis Pharmaceuticals, Inc. Supports for oligomer synthesis
AU2003224132A1 (en) * 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
WO2005021570A1 (ja) 2003-08-28 2005-03-10 Gene Design, Inc. Ｎ−０結合性架橋構造型新規人工核酸
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
AU2005272816B2 (en) * 2004-08-10 2011-08-11 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
SG157421A1 (en) 2005-01-14 2009-12-29 Dow Global Technologies Inc Reclamation of a titanosilicate, and reconstitution of an active oxidation catalyst
DK2314594T3 (da) 2006-01-27 2014-10-27 Isis Pharmaceuticals Inc 6-modificerede bicykliske nukleinsyreanaloger
CN101490074B (zh) 2006-05-11 2013-06-26 Isis制药公司 5’-修饰的双环核酸类似物
US20080068922A1 (en) 2006-09-12 2008-03-20 Voss Klaus-W Device for blending a binder component and a hardener component for producing a ready-made filler
JP2008068470A (ja) 2006-09-13 2008-03-27 Kyocera Mita Corp 電子機器、ジョブデータ認証受信プログラム
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
WO2009061841A2 (en) * 2007-11-05 2009-05-14 Isis Pharmaceuticals, Inc. Modified polynucleotides as antidotes to antisense compounds
WO2009076400A2 (en) * 2007-12-10 2009-06-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor vii gene
WO2010055041A1 (en) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of factor vii genes

Also Published As

Publication number Publication date
AU2008323970A1 (en) 2009-05-14
BRPI0820391A2 (pt) 2015-05-19
EP3000884B1 (en) 2018-09-12
WO2009061851A3 (en) 2009-07-16
EP2227545A2 (en) 2010-09-15
AU2008323970B2 (en) 2014-05-08
CA2705316A1 (en) 2009-05-14
US20100298417A1 (en) 2010-11-25
US9029337B2 (en) 2015-05-12
KR20100105550A (ko) 2010-09-29
CN102076852A (zh) 2011-05-25
RU2010119775A (ru) 2011-12-27
EP3000884A1 (en) 2016-03-30
NZ585250A (en) 2012-06-29
WO2009061851A2 (en) 2009-05-14
JP2011502514A (ja) 2011-01-27
IL205536A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
MX2010005055A (es) Modulacion de la expresion del factor 7.
WO2010045509A3 (en) Modulation of factor 11 expression
MX2022005200A (es) Composiciones y metodos para modular la expresion de angiotensinogeno.
MX2020004209A (es) Composiciones y metodos para modular la expresion de la apolipoproteina c-iii.
WO2010121074A8 (en) Modulation of inflammatory responses by factor xi
MX2020007078A (es) Composiciones y metodos para la expresion de arns guias crispr que usan el promotor h1.
MX2012013031A (es) Potenciadores alostericos mglur4 de sulfona heterociclica, composiciones y metodos para tratar disfuncion neurologica.
MX2012002269A (es) Metodos y composiciones para el tratamiento de trastornos fibroticos pulmonares.
MX2017012426A (es) Composiciones y metodos para modular la expresion de tmprss6.
EP2623586A3 (en) Compositions and methods for surface treatment with lipases
WO2009045370A3 (en) Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MY170910A (en) Processing biomass
EP2490529A4 (en) ALLOSTERIC POTENTIALIZERS OF MGLUR4, COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTION
MX339205B (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
IL200660A (en) Methods for producing 2,1-propanediol and e. coli is adapted to use these methods
MX2011010449A (es) Derivados de oxadiazol.
ZA201004224B (en) Production of food products with enhanced in mouth and mental refreshment
MX2017012308A (es) Heterociclilmetil-tienouracilo como agonistas del receptor de adenosina a2b.
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
PH12014501169B1 (en) Thrombin-binding antibody molecules and uses thereof
IL232105A0 (en) 3, 4-di-converted pyridine compound, methods of use and preparations containing it
MX2015005734A (es) Metodos de tratamiento de enfermedades hepaticas.
WO2012064758A3 (en) Methods for modulating factor 12 expression
WO2013074816A3 (en) Novel inhibitors of nox1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal